Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1271
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 841–852 of 1,271 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06075667
Site status not listed — check the official record
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
Decatur, Georgia • Meridian, Idaho • Topeka, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Recruiting Not applicable Interventional

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

NCT05934487
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Interventions
Cordella™ Pulmonary Artery Sensor System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Recruiting Not applicable Interventional

Ansa Cervicalis and Hypoglossal Nerve Stimulation in OSA

NCT05501236
Status at this site: Recruiting
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Grass S88 Muscle Stimulator
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Recruiting No phase listed Observational

Clinical Outcome Measure at Stryker Spine

NCT06226272
Status at this site: Recruiting
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Scoliosis
Interventions
Spinal Fusion, Spinal Deformities Correction
Device
Lead sponsor
VB Spine, LLC
Industry
Eligibility
18 Years and older
Enrollment
5,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
Jacksonville, Florida • Scarborough, Maine • Southfield, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Active, not recruiting Phase 1 Interventional

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881
Site status not listed — check the official record
View directory record Official record
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Interventions
mRNA-1345, mRNA-1365, Placebo, Nimenrix
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
5 Months to 24 Months
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

AlloSure Lung Assessment and Metagenomics Outcomes Study

NCT05050955
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Recruiting Phase 4 Interventional

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

NCT06016855
Status at this site: Recruiting
View directory record Official record
Conditions
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Interventions
Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Recruiting Phase 2 Interventional

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

NCT05770531
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Active, not recruiting Not applicable Interventional Results available

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT01586910
Site status not listed — check the official record
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Recruiting No phase listed Observational

Metastatic Leiomyosarcoma Biomarker Protocol

NCT05653388
Status at this site: Recruiting
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Plasma Collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Santa Monica, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Recruiting No phase listed Observational

A Study to Assess Growth in Children With Idiopathic Short Stature

NCT06309979
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
2 Years to 16 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 5, 2026, 12:51 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162
Site status not listed — check the official record
View directory record Official record
Conditions
COVID-19
Interventions
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 5, 2026, 12:51 PM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.